Home › Post-Concussion Syndrome › NCT04685772
Assessment of the Efficacy of Medrol Dose Pack for Acute Post-Concussive Headaches
Assessment of the Efficacy of Medrol Dose Pack for Post-Concussive Headaches
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Provision of signed and dated informed consent form (in person or via telehealth) 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, aged \>18 years old 4. Ability to take oral medication and be willing to adhere to the study regimen as described in this protocol 5. Patients presenting with all types of post-concussive headache with \>5/10 in severity on the numerical analog scale. 6. Headache that occurs for \> 4 hours per day 7. Headache that occurs every day 8. Headache that began after concussion, patient was diagnosed at an outpatient clinic or was hospitalized 9. Headache developed within 7 days post-injury and patient presenting within 30 days from initial trauma 10. A diagnosis of concussion. 11. If a patient is taking another pain medication, this still be included in the stud Exclusion Criteria: 1. Any evidence of known intracranial hemorrhage on neuroimaging 2. Headache developing after 7 days post injury and patient presenting after 30 days from initial trauma 3. Headache occurs \< 4 hours per day 4. Headache does not occur daily 5. Age \< or = 18 6. Headache is \< 5 in severity on numerical analog scale 7. Presence of increase in intracranial pressure or papilledema 8. Any contraindication to corticosteroids 9. Allergy or sensitivity to corticosteroids 10. Active Tuberculosis 11. Active pregnancy 12. Currently on corticosteroids for another reason 13. Participants with fungal infection
About the study
This novel pilot project will assess the effectiveness of corticosteroids in treatment of acute post-concussion headache. The investigators hypothesize that the use of corticosteroids will cause significant headache reduction in frequency and/or intensity than individuals who undergo the current standard of care. Additionally, the investigators hypothesize that corticosteroid use will lead to a reduction in other somatic symptoms including vestibular symptoms, leading to quicker return to school, work, and/or ability to play sports.
What is being tested
- Methylprednisolone (drug)
Sponsor: Northwell Health · Participants: 25 · Started: Apr 1, 2021
Contact the study team
- Jamie Ullman, MD · Phone: (516) 562 4300
- Betsy Moclair, RN, CCRC · Phone: (516) 253-7753
Official record on ClinicalTrials.gov — NCT04685772
Locations in the U.S.
| New York | Northwell Health - North Shore University Hospital, Manhasset |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.